United Therapeutics price target raised to $130 from $120 at Argus Argus increased its price target on United Therapeutics after the company announced that the FDA had approved its extended-release tablets for the treatment of pulmonary arterial hypertension. The firm believes that United Therapeutics is a mid-cap growth company that appears to be priced similar to more mature, slower-growth pharma companies. It keeps a Buy rating on the stock.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.